Clinical Trial Update: Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity [Phase 2]

View source ↗

Summary

Phase 2 pilot study update of Genfit's GFT505 (elafibranor) in patients with atherogenic dyslipidemia and abdominal obesity; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abdominal Obesity
• Atherogenic Dyslipidemia

Drugs mentioned

• GFT505

Snippet

Sponsor: Genfit | Conditions: Atherogenic Dyslipidaemia, Abdominal Obesity | Phase 2 | Status: COMPLETED